东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02348 东瑞制药

交易中 09-14 11:09:28

0.995

+0.000

0.00%

最高0.995	最低0.995	成交量8.00万
今开0.995	昨收0.995	日振幅0.00%
总市值14.99亿	流通市值14.99亿	总股本15.07亿
成交额7.96万	换手率0.01%	流通股本15.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02348","market":"HK","secType":"STK","nameCN":"东瑞制药","latestPrice":0.995,"timestamp":1789351626758,"preClose":0.995,"halted":0,"volume":80000,"delay":0,"changeRate":0,"floatShares":1507000000,"shares":1507000000,"eps":0.16370153093236292,"marketStatus":"交易中","change":0,"latestTime":"09-14 11:09:28","open":0.995,"high":0.995,"low":0.995,"amount":79600,"amplitude":0,"askPrice":0.995,"askSize":120000,"bidPrice":0.985,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":0.17821016375956833,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789358400000},"marketStatusCode":2,"adr":0,"listingDate":1057852800000,"exchange":"SEHK","adjPreClose":0.995,"dividendRate":0.063317,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":1.813187,"lotSize":4000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02348","defaultTab":"news","newsList":[{"id":"1172772167","title":"东瑞制药：熊融礼增持，好仓比例升至40.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172772167","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172772167?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:41","pubTimestamp":1788774108,"startTime":"0","endTime":"0","summary":"熊融礼于2026年9月4日以每股均价0.99港元买入东瑞制药股份6.00万股，涉资约5.94万港元。熊融礼此次增持前持有东瑞制药好仓6.05亿股，占比40.16%；增持后持股量为6.05亿股，好仓比例升至40.17%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177732974","title":"东瑞制药：李其玲增持，好仓比例升至47.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177732974","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177732974?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:11","pubTimestamp":1788772262,"startTime":"0","endTime":"0","summary":"根据披露，李其玲于2026年9月3日以每股均价1.0000港元买入东瑞制药股份10.40万股，涉资约10.40万港元。李其玲此次增持前持有东瑞制药好仓7.11亿股，占比47.18%；增持后持股量为7.11亿股，好仓比例升至47.19%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127907903","title":"东瑞制药2026年8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127907903","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127907903?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:16","pubTimestamp":1788344174,"startTime":"0","endTime":"0","summary":"东瑞制药于2026年9月2日发布2026年8月股份变动月报表。报告显示，截至2026年8月31日，公司法定/注册股本与上月底保持一致，注册总股本维持为20,000,000,000股，每股面值为0.05港元，合计约10亿港元。公司确认已满足适用的公众持股量要求，报告期内并无股份发行、购回或注销事项。2023年购股权计划保持22,900,000份股份期权，报告期内有关该计划的持股数量未发生变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662603064","title":"东瑞制药：10月9日将派发股息0.015港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662603064","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662603064?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:30","pubTimestamp":1787913000,"startTime":"0","endTime":"0","summary":"南财智讯8月28日电，东瑞制药（02348.HK）公告，公司将于2026年10月9日派发截至2026年6月30日止六个月的中期股息，每股派发0.015港元。除净日为2026年9月22日，为符合获派股息资格，股份过户文件须于2026年9月23日16:30前递交；公司将于2026年9月24日至9月25日暂停办理股份过户登记手续，记录日期为2026年9月25日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858379945.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858379945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK1191","02348","VIG","BK4585","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050829","title":"东瑞制药2026年中期营收5.46亿元同比下降13.4%，净利润1.23亿元同比增长18.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050829","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196050829?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:25","pubTimestamp":1787912709,"startTime":"0","endTime":"0","summary":"东瑞制药发布截至2026年6月30日止六个月的财报。期内实现营收5.46亿元，同比下降13.4%。同期净利润为1.23亿元，同比增长18.0%。毛利为2.83亿元，同比减少9.9%，毛利率从上年同期的49.8%提升至51.8%。期间销售费用与管理费用均有所下降，研发投入约0.35亿元，占营收比重6.4%。经营活动现金流净流入约1.90亿元，相比去年同期的2.02亿元略有下滑。成本结构方面，销售及分销费约0.39亿元，同比减少30.6%；行政费用约0.62亿元，同比减少8.0%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药2026年中期营收5.46亿元同比下降13.4%，净利润1.23亿元同比增长18.0%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181244902","title":"东瑞制药宣布派发中期股息 每股0.015港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181244902","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181244902?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:19","pubTimestamp":1787912349,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）正式宣告，针对截至2026年12月31日止财政年度，公司将派发中期股息，每股金额为0.015港元。这一决定标志着公司在当前财年中的股东回报计划迈出关键一步。值得注意的是，此次派息方案展现了管理层对业绩稳定性的信心，同时也为投资者提供了切实的现金收益。在东瑞制药的财务规划中，此举无疑是对股东长期支持的一种积极回应。每股0.015港元的中期红利，虽数额不大，却透露出公司对资本配置的审慎态度与持续分红的承诺。此举或将进一步巩固市场对这家制药企业未来盈利前景的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112622","title":"东瑞制药(02348.HK)拟8月28日举行董事会会议审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112622","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659112622?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:57","pubTimestamp":1786697824,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨东瑞制药(02348.HK)宣布，公司将于2026年8月28日(星期五)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2026年6月30日止六个月之中期业绩及其刊发，以及考虑派付中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260814/32335295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124318854","title":"东瑞制药（02348）拟于2026年8月28日审议中期业绩及股息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1124318854","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124318854?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:37","pubTimestamp":1786696650,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司（股票代码：02348）8月14日公告，公司董事会已排定于2026年8月28日（星期五）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及相关公告，并同步讨论及考虑是否派发中期股息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166984249","title":"东瑞制药更新2026年7月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1166984249","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166984249?lang=zh_cn&edition=full","pubTime":"2026-08-05 15:11","pubTimestamp":1785913904,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于2026年8月5日发布截至2026年7月31日的股份变动月报表。报告显示，公司在报告期内已发行股本由上月底的1,506,391,000股增加至1,507,025,000股，增幅为634,000股。公司确认其公众持股量继续符合香港联交所规定的25%最低要求。公司注册股本维持在10亿港元不变，股份面值为每股0.05港元。2023购股权计划自5月25日采纳后，本月内授出10,000,000股期权并有2,500,000股失效，期末结存数量为22,900,000股期权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648663125","title":"东瑞制药(02348)授出合共1000万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2648663125","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648663125?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:04","pubTimestamp":1783076698,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东瑞制药(02348)发布公告，于2026年7月3日，公司根据2023购股权计划向集团若干合资格雇员授出合共1000万份购股权以认购股份，惟须待承授人接纳方可作实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153743637","title":"东瑞制药更新2026年6月股份变动月报表，股本增加至1,506,391,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1153743637","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153743637?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:44","pubTimestamp":1783075477,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于2026年7月3日发布截至2026年6月30日的股份变动月报表。公告显示，公司法定注册股本保持不变，仍为20,000,000,000股普通股，面值每股0.05港元，合计10亿港元。月报数据显示，公司已发行的普通股由2026年5月底的1,505,691,000股增至2026年6月底的1,506,391,000股，增加700,000股。2023购股权计划于本月内有600,000股期权失效，但无新股发行、购回或注销动作。本次公告由公司秘书彭洁玲签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208403","title":"东瑞制药：拟向上海建信东瑞生物医药创业投资基金出资1亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208403","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644208403?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:44","pubTimestamp":1781793840,"startTime":"0","endTime":"0","summary":"南财智讯6月18日电，东瑞制药（02348.HK）发布须予披露交易公告，于2026年6月18日，公司全资附属公司苏州东瑞作为有限合伙人，与中建信（有限合伙人）及上海建信（普通合伙人）订立有限合伙协议，拟共同设立上海建信东瑞生物医药创业投资基金合伙企业（有限合伙），苏州东瑞承诺出资最高达人民币100000000元，占合伙企业拟定资本的50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606183776507447.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606183776507447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","399441","02348","161726","BK4585","BK4581","BK1191","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167246926","title":"东瑞制药旗下苏州东瑞承诺最高投资1亿元于合作项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1167246926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167246926?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:38","pubTimestamp":1781793497,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司宣布，其旗下子公司苏州东瑞制药有限公司已承诺，将在一个合作项目中投资最高达人民币1亿元。此项投资承诺彰显了公司对特定合作领域或项目的战略重视与资源投入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141007370","title":"东瑞制药2026年5月股份变动月报表，新增1,968,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1141007370","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141007370?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:22","pubTimestamp":1780395756,"startTime":"0","endTime":"0","summary":"东瑞制药于2026年6月2日发布截至2026年5月31日的股份变动月报表。公告显示，公司法定股本维持在20,000,000,000股普通股不变，总额为1,000,000,000港元。根据月报，东瑞制药本月新增发行1,968,000股普通股，令已发行股份数量由上月末的1,503,723,000股增至1,505,691,000股，未持有任何库存股。公告称，截至2026年5月末，公司发行的普通股符合香港联交所对上市公司股份公众持股量的规定，且本月内不存在股份购回或注销活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132753574","title":"东瑞制药子公司盐酸曲唑酮片50毫克与100毫克获中国批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1132753574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132753574?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:43","pubTimestamp":1780044188,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司旗下子公司，已成功获得中国监管部门对盐酸曲唑酮片50毫克及100毫克两种规格的生产批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639286026","title":"东瑞制药(02348)：盐酸曲唑酮片50毫克及100毫克获得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639286026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639286026?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:42","pubTimestamp":1780044179,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东瑞制药(02348)发布公告，集团附属公司福建东瑞制药有限公司取得中国国家药品监督管理局有关盐酸曲唑酮片50毫克及100毫克的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。此产品适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均适用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东瑞制药(02348)：盐酸曲唑酮片50毫克及100毫克获得药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638750834","title":"东瑞制药(02348)附属取得琥珀酸曲格列汀片50毫克及100毫克的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2638750834","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638750834?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:32","pubTimestamp":1779870755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东瑞制药(02348)公布，集团的附属公司苏州东瑞制药有限公司是国内第二家企业取得中国国家药品监督管理局有关琥珀酸曲格列汀片50毫克及100毫克的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。此产品为口服降糖周制剂，可单药治疗用于2型糖尿病成人患者改善血糖控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187103365","title":"东瑞制药4月股份变动月报：股本增至1,503,723,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1187103365","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187103365?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:10","pubTimestamp":1777968656,"startTime":"0","endTime":"0","summary":"2026年5月5日，东瑞制药公布截至2026年4月30日的股份变动月报。公告显示，公司本月法定注册股本维持为20,000,000,000股普通股，每股面值0.05港元，总额1,000,000,000港元，较上月无变化。报告期内，公司已发行股份由上月底的1,503,605,000股增加118,000股至1,503,723,000股，主要因“2013购股权计划”下的期权行使所致；本月行使期权筹资金额为106,200港元。截至4月30日，公司库藏股份数目仍为零，同时本月内无任何购回及注销股份活动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128120013","title":"东瑞制药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1128120013","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128120013?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:12","pubTimestamp":1776942723,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于4月24日公告，董事会拟于即将召开的股东周年大会上寻求授权购回最多相当于公司已发行股本10%的股份。据披露，截至2026年4月20日，公司已发行股份总数为1,503,723,000股，如获批准，最多可回购150,372,300股。该购回计划将遵循开曼群岛适用法例及香港联交所上市规则进行，购回所需资金来自溢利或依法可动用的资本金。东瑞制药计划于5月22日召开股东周年大会，审议有关股份购回授权及其他事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154507051","title":"东瑞制药2025年报：收入同比增16.1%至12.31亿元，非经常性项目拖累净利下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1154507051","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154507051?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:11","pubTimestamp":1776942673,"startTime":"0","endTime":"0","summary":"东瑞制药于本报告期实现收入约人民币12.31亿元，同比增长约16.1%。扣除一次性处置股权及相关投资损失等非经常性影响后，经营利润较上一年度有所增长，但归属于母公司拥有人应占溢利仍录得约人民币2.14亿元，同比下降约62.1%。董事会建议派发末期股息每股港币0.048元，合计约港币7,217.1万元，使本期股息支付率上升至约39.3%。公司聘请安永会计师事务所担任年度核数师，核数师意见认为财务报表在所有重大方面均能公平反映公司的财务状况与经营成果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药2025年报：收入同比增16.1%至12.31亿元，非经常性项目拖累净利下滑","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dawnrays.com","stockEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0613},{"period":"6month","weight":-0.0796},{"period":"1year","weight":-0.1437},{"period":"ytd","weight":-0.1474}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东瑞制药（控股）有限公司是一家主要从事非专利药物的开发、制造及销售业务的投资控股公司。该公司通过两个部门运营业务。成药分部从事制造及销售成药。中间体及原料药分部从事制造及销售中间体及原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":0.000714},{"month":2,"riseRate":0.478261,"avgChangeRate":-0.003766},{"month":3,"riseRate":0.478261,"avgChangeRate":0.017595},{"month":4,"riseRate":0.695652,"avgChangeRate":0.037646},{"month":5,"riseRate":0.478261,"avgChangeRate":0.016893},{"month":6,"riseRate":0.565217,"avgChangeRate":0.007062},{"month":7,"riseRate":0.565217,"avgChangeRate":0.018727},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.017986},{"month":9,"riseRate":0.458333,"avgChangeRate":0.020171},{"month":10,"riseRate":0.434783,"avgChangeRate":-0.001342},{"month":11,"riseRate":0.565217,"avgChangeRate":0.035884},{"month":12,"riseRate":0.565217,"avgChangeRate":0.012599}],"exchange":"SEHK","name":"东瑞制药","nameEN":"DAWNRAYS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东瑞制药(02348)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东瑞制药,02348,东瑞制药股票,东瑞制药股票老虎,东瑞制药股票老虎国际,东瑞制药行情,东瑞制药股票行情,东瑞制药股价,东瑞制药股市,东瑞制药股票价格,东瑞制药股票交易,东瑞制药股票购买,东瑞制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东瑞制药(02348)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}